FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer
We recently synthesized a series of novel makaluvamine compounds, and found that the most potent was FBA-TPQ. The effects of FBA-TPQ on human (LNCaP and PC3) and murine (TRAMP C1) prostate cancer cells were evaluated. Potential mechanisms of action of the compound were also determined. FBA-TPQ exhibited dose-dependent cytotoxicity in the low micromolar range, inhibited proliferation, caused cell cycle arrest, and induced apoptosis in prostate cancer cell lines. The compound also decreased the expression of the androgen receptor and PSA. The results presented herein support the further development of FBA-TPQ as a novel agent for prostate cancer.
KeywordsMakaluvamine Prostate cancer Chemotherapy Cell cycle Apoptosis
This work was supported by NIH grants R01 CA112029 and R01 CA121211. E. Rayburn was supported by a DoD grant (W81XWH-06-1-0063) and a T32 fellowship from the NIH/UAB Gene Therapy Center (CA075930). The apoptosis analyses were performed by the Flow Cytometry Core of the Arthritis and Musculoskeletal Center, which is supported in part by an NIH grant (P60 AR20614). S. E. Velu was supported by a translational research grant from the UAB Council of University-Wide Interdisciplinary Research Centers.
- 1.American Cancer Society, Inc. Leading Sites of New Cancer Cases and Deaths-2007 Estimates. Surveillance Research. 2007. Available online. http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf. Accessed 9 December 2008
- 16.Jiang C, Lee HJ, Li GX et al (2006) Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Res 66:453–463 doi: 10.1158/0008-5472.CAN-05-1865 CrossRefPubMedGoogle Scholar